@article{bc2cf03492644f8e8480dd161795d696,
title = "Reply to comment on: {"}Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis{"}",
keywords = "Antibodies, Monoclonal, Humanized/therapeutic use, Biological Therapy, Colitis, Ulcerative/drug therapy, Crohn Disease/drug therapy, Gastrointestinal Agents/therapeutic use, Humans",
author = "Mohamed Attauabi and Seidelin, \{Jakob Benedict\} and Johan Burisch",
year = "2023",
month = feb,
doi = "10.1016/j.dld.2022.11.009",
language = "English",
volume = "55",
pages = "300--301",
journal = "Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver",
issn = "1590-8658",
publisher = "Elsevier BV",
number = "2",
}